Loading…

Effectiveness and safety of bee venom pharmacopuncture for rheumatoid arthritis: a systematic review protocol

IntroductionRheumatoid arthritis (RA) is the common autoimmune disease with low quality of life. The representative treatment is medication and medication usage has improved through update of clinical guidelines, however, there are still limitations. Bee venom (BV) has been reported to have meaningf...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open 2022-03, Vol.12 (3), p.e056545-e056545
Main Authors: Sung, Won-Suk, Kim, Jung-Hyun, Lee, Dong Hyuk, Kim, Eun-Jung, Seo, Byung-Kwan, Hong, Seung-Ug, Baek, Yong-Hyeon, Lee, Kwang Ho, Kim, Joo-Hee
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IntroductionRheumatoid arthritis (RA) is the common autoimmune disease with low quality of life. The representative treatment is medication and medication usage has improved through update of clinical guidelines, however, there are still limitations. Bee venom (BV) has been reported to have meaningful therapeutic effects and the possibility of alternative options for RA through several types of studies, but there is no well-organised and recent published systematic review (SR).MethodsWe will search randomised controlled trials about the BV on RA from the inception to 31 May 2022 in various databases, manual research and contacting authors. Electronic databases will include MEDLINE, EMBASE, Cochrane library, China National Knowledge Infrastructure, CiNii, J-STAGE, KoreaMed, Korean Medical Database, Korean Studies Information Service System, National Digital Science Library, Korea Institute of Science and Technology Information and Oriental Medicine Advanced Searching Integrated System. With screening and reviewing process, we will identify the eligible studies and extract the needed data. The primary outcome will be the disease activity scores indicating the improvement of RA symptoms (American College of Rheumatology response criteria 20, 50, 70), functions (Health Assessment Questionnaire, Disease Activity Score of 28 joints), joint (Western Ontario and McMaster universities osteoarthritis index), pain (Visual Analogue Scale, Numerical Rating Scale) and effective rate. The secondary outcomes will be the RA-related blood test levels and adverse events. We will perform a meta-analysis by Review Manager software, the assessment of risk of bias by Cochrane Collaboration ‘risk of bias’ and the determination of quality of evidence by Grades of Recommendation, Assessment, Development and Evaluation.Ethics and disseminationOur SR will suggest the clinical evidence of the use of BV for RA to patient, clinicians and policymakers. We will publish our results in a peer-review journal.PROSPERO registration numberCRD42021238058.
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2021-056545